RxDoctor Payments Data

Mousa Matar, MD

Internal Medicine · Riverside, CANPI 1992116982

Payments from drug & device makers

$1,399in general payments, 2019–2025

Across 67 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$334
  • Johnson & Johnson$127
  • Amgen$88
  • AbbVie$79
  • Boehringer Ingelheim$78
  • Merck$77
  • plus $615 from 16 others

What the payments were for

  • Food & beverage$1,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,399 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$414,694
Medicare patients
596
Services billed
3,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban313$168,065
XifaxanRifaximin18$37,257
XareltoRivaroxaban40$25,483
EntrestoSacubitril/Valsartan41$22,146
JanuviaSitagliptin Phosphate33$21,944
Voriconazole11$20,407
SantylCollagenase Clostridium Hist.35$16,678
JardianceEmpagliflozin27$11,334
FarxigaDapagliflozin Propanediol12$11,310
Atorvastatin Calcium652$7,188
Breo ElliptaFluticasone/Vilanterol18$7,057
PremarinEstrogens, Conjugated11$6,595
Enoxaparin Sodium55$6,421
TradjentaLinagliptin13$6,167
Levothyroxine Sodium332$4,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$30$174,660324 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$39$37,25718 claims
Johnson & JohnsonXarelto$127$25,48340 claims
NovartisEntresto$62$22,14641 claims
MerckJanuvia$77$21,94433 claims
Boehringer IngelheimJardiance, Tradjenta$78$17,50140 claims
AstraZenecaFarxiga$334$11,31012 claims
GSKBreo Ellipta$40$7,05718 claims
AbbVieSynthroid$79$3,12735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →